tiprankstipranks
Trending News
More News >
AEVIS VICTORIA SA (CH:AEVS)
:AEVS
Switzerland Market

AEVIS VICTORIA SA (AEVS) AI Stock Analysis

Compare
2 Followers

Top Page

CH:AEVS

AEVIS VICTORIA SA

(AEVS)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 4o)
Rating:44Neutral
Price Target:
CHF11.00
▼(-19.71% Downside)
AEVIS VICTORIA SA's overall stock score is primarily impacted by its financial challenges, including high leverage and net losses, and bearish technical indicators. The stock's high P/E ratio suggests overvaluation, further weighing down the score.
Positive Factors
Revenue Growth
AEVIS VICTORIA SA's consistent revenue growth reflects its expanding market presence and effective business strategies in the healthcare sector.
Operational Efficiency
Improved EBITDA margin indicates better cost management and operational efficiency, which can enhance long-term profitability.
Gross Profit Margin
A strong gross profit margin suggests effective pricing and cost control, providing a buffer against market fluctuations.
Negative Factors
High Leverage
Significant leverage can increase financial risk and limit the company's ability to invest in growth opportunities.
Persistent Net Losses
Ongoing net losses undermine financial stability and may hinder AEVIS's ability to reinvest in its business.
Negative Free Cash Flow
Negative free cash flow indicates difficulties in funding operations and growth without external financing, posing long-term financial challenges.

AEVIS VICTORIA SA (AEVS) vs. iShares MSCI Switzerland ETF (EWL)

AEVIS VICTORIA SA Business Overview & Revenue Model

Company DescriptionAevis Victoria SA engages in healthcare, hospitality, lifestyle, and infrastructure sectors in Switzerland. The company operates through Hospitals, Hospitality, Telemedicine, and Real Estate segments. It operates 22 hospitals with 1,496 beds; manages with a total of 941 rooms with a total rentable surface of 188,109 sqm. It also provides telemedicine, and ambulance and day clinic services. In addition, it engages in the patient hotel, better aging, radiology institute, pharmacy, ophthalmology, real estate management, stem cells, cosmetics, and publishing businesses, as well as organizes seminars. The company is headquartered in Fribourg, Switzerland. Aevis Victoria SA is a subsidiary of M.R.S.I. Medical Research, Services and Investments S.A.
How the Company Makes MoneyAEVIS generates revenue through several key streams, including rental income from its real estate holdings in the healthcare sector, management fees from its private equity investments, and operational revenues from healthcare services offered through its portfolio companies. The company often enters into strategic partnerships with healthcare providers and institutions, which can enhance its service offerings and create additional revenue opportunities. Additionally, AEVIS benefits from capital appreciation of its investments as it strategically positions itself in growing markets within the healthcare and wellness industries.

AEVIS VICTORIA SA Financial Statement Overview

Summary
AEVIS VICTORIA SA shows mixed financial performance with revenue growth and improved operational efficiency, but persistent net losses and high leverage pose significant risks. The company needs to enhance profitability and cash flow generation.
Income Statement
60
Neutral
AEVIS VICTORIA SA has shown a mixed performance in its income statement. The revenue growth from 2023 to 2024 was approximately 10.5%, indicating a positive trend. However, the company has been facing persistent EBIT losses, impacting its profitability. The gross profit margin for 2024 is robust at 78.2%, but the net profit margin remains negative due to net losses. EBITDA margin improved, suggesting operational efficiencies, but overall profitability remains a concern.
Balance Sheet
55
Neutral
The company's balance sheet indicates a high debt-to-equity ratio of approximately 2.02, which suggests significant leverage. The equity ratio stands at 26.5%, reflecting moderate equity financing. Return on equity is negative due to net losses, posing a risk to financial stability. Despite these issues, the company has managed to increase its stockholders' equity over the years, showing resilience.
Cash Flow
50
Neutral
AEVIS VICTORIA SA's cash flow statement shows challenges in generating free cash flow, which has remained negative in recent years. However, there was an improvement in operating cash flow in 2024 compared to 2023. The free cash flow to net income ratio is not favorable due to losses, and the operating cash flow to net income ratio highlights the difficulty in translating earnings into cash. The company needs to improve its cash generation to support operations and growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue999.58M1.01B914.36M1.03B823.26M696.57M
Gross Profit251.81M789.90M170.09M185.41M137.56M112.46M
EBITDA91.21M92.49M49.06M128.29M83.47M34.48M
Net Income2.09M-2.87M-39.30M58.81M-4.26M-31.80M
Balance Sheet
Total Assets1.93B2.00B1.86B1.79B1.73B1.53B
Cash, Cash Equivalents and Short-Term Investments23.52M36.92M80.71M75.43M63.42M65.56M
Total Debt194.29M1.07B1.01B970.03M841.27M841.74M
Total Liabilities1.34B1.42B1.32B1.28B1.14B1.11B
Stockholders Equity537.27M530.85M491.89M469.34M485.92M361.23M
Cash Flow
Free Cash Flow39.05M-18.80M-66.06M40.28M-24.07M-283.46M
Operating Cash Flow71.57M46.50M42.67M114.30M33.53M23.77M
Investing Cash Flow54.26M-62.28M35.56M-56.82M21.63M-297.14M
Financing Cash Flow-133.42M-28.06M-72.95M-45.46M-57.31M298.71M

AEVIS VICTORIA SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price13.70
Price Trends
50DMA
13.25
Positive
100DMA
13.28
Positive
200DMA
13.33
Positive
Market Momentum
MACD
0.14
Negative
RSI
55.29
Neutral
STOCH
80.09
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:AEVS, the sentiment is Positive. The current price of 13.7 is above the 20-day moving average (MA) of 13.56, above the 50-day MA of 13.25, and above the 200-day MA of 13.33, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 55.29 is Neutral, neither overbought nor oversold. The STOCH value of 80.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:AEVS.

AEVIS VICTORIA SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
CHF3.68B18.854.14%2.66%2.91%
65
Neutral
CHF3.79B14.524.46%-4.68%-5.79%
64
Neutral
CHF2.33B59.760.68%27.24%122.39%
55
Neutral
CHF1.31B80.750.77%-3.45%-49.82%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
44
Neutral
CHF1.16B554.669.72%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:AEVS
AEVIS VICTORIA SA
13.70
-0.55
-3.86%
CH:ADEN
Adecco Group AG
22.62
1.82
8.75%
CH:DKSH
DKSH Holding AG
56.70
-11.88
-17.32%
CH:COTN
COMET Holding AG
299.40
34.84
13.17%
CH:XLS
Xlife Sciences Ltd.
23.00
2.40
11.65%
CH:SKAN
SKAN Group AG
58.10
-20.04
-25.65%

AEVIS VICTORIA SA Corporate Events

AEVIS VICTORIA Cuts Financing Costs with Comprehensive Group-Wide Refinancing
Dec 29, 2025

AEVIS VICTORIA SA has completed a comprehensive refinancing programme across its group, aimed at optimising its capital and financing structure and improving financial flexibility. At the holding level, the company has secured a new syndicated financing facility, while in the real estate segment it has refinanced a 2020 bridge loan used for hotel acquisitions with long-term mortgage financing and obtained a new facility for London’s Hotel L’Oscar. These measures extend and diversify the maturity profile of AEVIS’s liabilities and, together with a reduction of more than CHF 100 million in consolidated liabilities in the first half of 2025, are expected to significantly lower the group’s cost of debt and financial expenses, delivering annual interest savings in the high single-digit million range.

The most recent analyst rating on (CH:AEVS) stock is a Buy with a CHF17.00 price target. To see the full list of analyst forecasts on AEVIS VICTORIA SA stock, see the CH:AEVS Stock Forecast page.

AEVIS VICTORIA SA Reports Strong Revenue Growth and Strategic Review
Nov 3, 2025

AEVIS VICTORIA SA reported an 18.2% revenue growth in the first nine months of 2025, driven by strong performance in its healthcare and hospitality sectors. The Swiss Medical Network saw significant growth through the integration of new units, while its hospitality division benefited from Switzerland’s increasing appeal as a travel destination. The company is reviewing strategic options for its subsidiaries to support long-term development, including potential new strategic shareholders and exploring capital options for Infracore.

The most recent analyst rating on (CH:AEVS) stock is a Hold with a CHF13.50 price target. To see the full list of analyst forecasts on AEVIS VICTORIA SA stock, see the CH:AEVS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 02, 2025